Records how SGLT2 inhibitor medicines are used in adults with congenital heart disease
Studies safety and effects of SGLT2 inhibitor medicines in adults with congenital heart disease.
Plain-language title generated from the registry record
Registry title: Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Key facts
- Where
- Baltimore, Grand Rapids, and New York, United StatesSee the 3 sites
Where in United States
- Johns Hopkins UniversityBaltimore, United StatesTaking people
- Helen DeVos Children's HospitalGrand Rapids, United StatesTaking people
- Mount Sinai Fuster Heart HospitalNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leiden University Medical Center
- Trial code
- NCT06932081
- Record updated
- 13 February 2026
- Original description
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.Read full original descriptionShow less
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Inclusion: Congenital heart defect; Age ≥ 18 years; Initiated on treatment with an SGLT2i.
Exclusion: No consent for data collection.